FindTrial
Sign In

Efficacy and safety of Qingfei Paidu Decoction (Granules) in the treatment of COVID-19

Efficacy and safety of Qingfei Paidu Decoction (Granules) in the treatment of COVID-19

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042177
Enrollment
Unknown
Registered
2021-01-15
Start date
2020-02-01
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Qingfei Paidu Decoction (Granules) combined with general treatment group:Nil
General treatment group:Nil

Sponsors

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: Conform to the Diagnosis and Treatment Protocol for COVID-19 (trial version 4-7).

Exclusion criteria

Exclusion criteria: Combined with severe primary respiratory disease, or other microbial pneumonia that needs to be identified from 2019-nCOV.

Design outcomes

Primary

MeasureTime frame
Rate of disease progression;—

Secondary

MeasureTime frame
Total antifebrile time;Cough relief time;Virus turn negative time;Imaging efficiency;Length of stay;Cure rate;—

Countries

China

Contacts

Public ContactWang Yanping

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

iso_office@vip.126.com+86 10-64093279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026